Artal Group S.A. Arcus Biosciences, Inc. Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2019 Nov 14, 2019	SELL	$6.44 - $10.18 $1.74 Million - $2.75 Million	-270,000 Closed	0 $0
Q2 2019 Aug 09, 2019	SELL	$7.29 - $13.38 $218,700 - $401,400	-30,000 Reduced 10.0%	270,000 $2.15 Million
Q1 2018 May 10, 2018	BUY	$15.44 - $17.71 $4.63 Million - $5.31 Million	300,000 New	300,000 $4.63 Million

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.09B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.